Reduction in Wearable-Derived Maximal Oxygen Consumption (VO₂max) During Tamsulosin Use in an Endurance Athlete
Abstract
α₁-adrenergic antagonists such as tamsulosin are widely prescribed for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. While their systemic vascular effects are well recognized, their impact on aerobic performance remains unclear. We describe a case of a competitive endurance athlete who observed a decline in wearable-derived maximal oxygen consumption (VO₂max) temporally associated with tamsulosin therapy. A male endurance runner with LUTS was initiated on treatment with tamsulosin. Subsequently, he noted an increased perceived level of exertion during training and a reduction in estimated VO₂max during activity as recorded by his smartwatch. Longitudinal running data from his device were reviewed across three consecutive time periods: prior to initiation of tamsulosin (from August 15, 2022, to March 1, 2023), during daily tamsulosin therapy (from March 1, 2023, to February 7, 2024), and following transition to daily tadalafil therapy (from February 7, 2024, to June 15, 2024). A total of 113 outdoor running sessions were included, demonstrating a decline in estimated VO₂max from baseline pre-tamsulosin (48.19 mL/kg/minute) to daily tamsulosin use (45.68 mL/kg/minute) (p = 6.42 × 10-11), with partial recovery after initiation of tadalafil (46.21 mL/kg/minute) (p = 6.77 × 10-5). This pattern was also observed among runs performed at similar paces. Although causality cannot be established from a single observation, this case suggests that…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.